US 11633416
Oral formulations of CD73 compounds
granted A61KA61K31/58A61K31/7064
Quick answer
US patent 11633416 (Oral formulations of CD73 compounds) held by Arcus Biosciences, Inc. expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Arcus Biosciences, Inc.
- Grant date
- Tue Apr 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 24
- CPC classes
- A61K, A61K31/58, A61K31/7064, A61K47/183, A61K47/24